MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Chicago, IL, March 2, 2026 — MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company specializing in targeted immunotherapies for cancer, has announced a significant corporate development: the commencement of an underwritten public offering of shares of its common stock and, for certain investors, pre-funded warrants to purchase common shares.

Key Points and Details of the Offering

• Type of Offering: MAIA is offering shares of common stock and pre-funded warrants (in lieu of common stock for certain investors). All securities in this offering are being issued by the company itself.
• Over-Allotment Option: The company intends to grant underwriters a 30-day option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions.
• Bookrunner: Konik Capital Partners, LLC, a division of T.R. Winston & Company, is acting as the sole book-running manager for the offering.
• Use of Proceeds: The net proceeds from the offering will be used to fund clinical trials, working capital, and general corporate purposes, all of which are critical for the continued development and commercialization of MAIA’s pipeline.
• Registration Status: The securities are being offered under a shelf registration statement on Form S-3 (File No. 333-273984), declared effective by the SEC on August 23, 2023. The offering will be made only through a prospectus supplement and an accompanying prospectus.
• Access to Materials: The preliminary prospectus supplement and accompanying prospectus will be available on the SEC website (www.sec.gov) and from Konik Capital Partners. Interested investors are urged to read these documents in their entirety.

About MAIA Biotechnology

MAIA Biotechnology is a targeted therapy and immuno-oncology company focused on the development and commercialization of potentially first-in-class drugs with novel mechanisms of action. The company’s lead program is ateganosine (THIO), a cancer telomere targeting agent currently in clinical development for treating non-small cell lung cancer (NSCLC) patients with telomerase-positive cancer cells.

For more information, visit www.maiabiotech.com.

Important Information for Shareholders

• Potential Share Price Impact: The announcement of a public offering is a material event. Such offerings can be dilutive to existing shareholders and may impact share price, depending on the offering size, pricing, and investor demand.
• Uncertainty: The offering is subject to market and other conditions. There is no assurance as to whether or when the offering will be completed, or what its size or terms will be. This uncertainty may also affect share price sentiment.
• Forward-Looking Statements: The company has issued caution regarding forward-looking statements, which include its plans for clinical trials, product development, regulatory filings, and commercialization. These statements are subject to risks and uncertainties that could materially impact actual results.
• Regulatory Compliance: No offer to sell or solicitation to buy securities will be made in any jurisdiction where such action would be unlawful without registration or qualification under applicable laws.
• Investor Relations Contact: For further information, investors can reach out to MAIA at +1 (872) 270-3518 or [email protected].

Potential Catalysts and Risks

• Catalysts: The proposed offering, if successful, will provide MAIA with additional capital to advance its clinical programs, particularly the development of its lead asset, THIO. Progress in clinical trials or positive regulatory developments can act as share price catalysts.
• Risks: Any delay, reduction in offering size, or failure to complete the offering as planned could negatively impact the company’s operational plans and, by extension, its stock performance. Investors should carefully review the risk factors detailed in MAIA’s SEC filings, including Forms 10-K and 10-Q.

Disclaimer

This article is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities. All forward-looking statements are based on current management expectations and are subject to risks and uncertainties. Investors are strongly urged to read the prospectus supplement and accompanying prospectus, along with other SEC filings, before making any investment decision. Past performance is not indicative of future results.

View MAIA Biotechnology, Inc. Historical chart here